2021 El Sallvador Nucleic Acid Testing/NAT Market Assessment--Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts for 100 Infectious, Genetic, Cancer, Forensic and Paternity Tests

2021 El Sallvador Nucleic Acid Testing/NAT Market Assessment--Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts for 100 Infectious, Genetic, Cancer, Forensic and Paternity Tests

  • February 2021 •
  • 1120 pages •
  • Report ID: 6027442 •
  • Format: PDF
2021 El Sallvador Nucleic Acid Testing/NAT Market Assessment--Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts for 100 Infectious, Genetic, Cancer, Forensic and Paternity Tests--Latest Technologies and Instrumentation Pipeline, Emerging Opportunities for Suppliers

This new report is designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities in the molecular diagnostics market during the next five years. The report is available by section, and can be customized to specific information needs and budget.

Highlights

- Five-year test volume and sales forecasts
- Feature comparison of major analyzers
- Profiles of market players and start-up firms developing innovative technologies
  and products
- Specific product and business opportunities for instrument and consumable suppliers

Rationale

The molecular diagnostics market is unquestionably the most rapidly growing segment of the in vitro diagnostics industry. The next five years will witness significant developments in reagent systems and automation, as well as introduction of a wide range of new products that will require innovative marketing approaches. The rate of market penetration into routine clinical laboratories, however, will depend on the introduction of cost-effective and automated systems with amplification methods.

In order to successfully capitalize on the opportunities presented by the molecular diagnostics market, many companies are already exploiting new molecular technologies as corporate strategic assets, managed in support of business and marketing strategies. Integrating new technology planning with business and corporate strategies will be one of the most challenging tasks for diagnostic companies during the next five years.

Market Segmentation Analysis

- Sales and market shares of key suppliers of molecular diagnostic reagent kits and components in major markets.

Five-year test volume and sales forecasts for major applications, including:

- Infectious Diseases

- Forensic Testing

- Cancer

- Paternity Testing/HLA Typing

- Genetic Diseases

- Others

- Five-year test volume and sales projections for over 30 NAT assays.

- A comprehensive analysis of the sequencing market, by country and laboratory segment, including:

- Industrial

- Academic

- Government

- Commercial

- Market segmentation analysis, including review of the market dynamics, trends, structure, size, growth and suppliers in major countries.

Product/Technology Review

- Comparison of leading molecular diagnostic analyzers marketed by Abbott, Beckman Coulter, BD, Bio-Rad, Gen-Probe, Roche, Tecan and other suppliers.

- Extensive review of molecular diagnostic technologies, test formats, detection methodologies, trends in testing automation and over 30 target/signal amplification methods, including:

- PCR

- bDNA

- SDA

- NASBA

- TMA

- SSSR, and others

- LCR

- Universities and research centers developing new molecular diagnostic technologies and products.

Competitive Assessments

- Extensive strategic assessments of major suppliers and emerging market entrants, including their sales, product portfolios, marketing tactics, collaborative arrangements and new technologies/products in R&D.

- Companies developing and marketing molecular diagnostics products, by test and application.

Opportunities and Strategic Recommendations

- Specific new product development opportunities with potentially significant market appeal during the next five years.

Contains 1,120 pages and 48 tables

Companies Profiled

Competitive Assessments

- Abbott
- Affymetrix
- Agilent Technologies
- Applied Gene Technologies
- Arca Biopharma
- Beckman Coulter/Danaher
- Becton Dickinson
- Biokit
- bioMerieux
- Bio-Rad
- Biotest
- Cepheid
- Decode Genetics
- Diadexus
- Eiken Chemical
- Elitech Group
- Enzo Biochem
- Exact Sciences
- Fujirebio
- Grifols
- Hologic
- Illumina
- LabCorp
- Leica Biosystems
- Li-Cor Biosciences
- Myriad Genetics
- Ortho-Clinical Diagnostics
- PerkinElmer
- Proteome Sciences
- Qiagen
- Roche
- Scienion
- Sequenom
- Shimadzu
- Siemens Healthineers
- Sierra Molecular
- Takara Bio
- Tecan Group
- Thermo Fisher